Adapted from: AACE/ACE Obesity CPG, Endocr Pract
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: a 52-week open-label, multicenter, post-marketing clinical study
It is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, which may lead to enhanced weight loss and metabolic effects compared to single or dual agonists
The model empowers patients, shortens the treatment journey, and opens new opportunities for digital engagement
PBH is also associated with a high degree of disability and can result in major disruptions to life, including falls, motor vehicle accidents, and job and income loss
Hao, Z., Jin, D